GNPXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Genprex, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$2.06−0.05 (-2.37%)
Close on Oct 19, 2026
- Market cap
- $974.71K
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$397.17 (−99.48%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Split
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $974.71K
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.07
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$16.50M
- Book value per share
- $31.27
- Diluted shares
- 0M
Eleven years at a glance
Fiscal years 2015 to 2025 and trailing twelve months, USD
Revenue
–
Operating income
-$15.84M
Net income
-$16.50M
EPS, diluted
–
Free cash flow
–
Reported periodTrailing twelve months